Muscarinic Antagonist
Breakthroughs in Schizophrenia Treatment With Muscarinic Agents
This activity is supported by an educational grant from Bristol Myers Squibb.
Aclidinium safe, beneficial in COPD patients with, without prior exacerbations
NEW ORLEANS — In a subgroup analysis of the ASCENT-COPD trial, treatment with the long-acting antimuscarinic bronchodilator aclidinium bromide reduced the risk for new exacerbations compared with placebo in patients with moderate to very severe COPD and high cardiovascular risk, regardless of prior exacerbations.
Three-in-one asthma inhaler may improve lung function, reduce exacerbations
The addition of a long-acting muscarinic antagonist to inhaled corticosteroid plus long-acting beta-2 agonist therapy in a single inhaler improves lung function and reduces exacerbations among patients with uncontrolled asthma, according to data from two phase 3 studies presented at the European Respiratory Society International Congress.
Targeted lung denervation safely reduces respiratory events in COPD
Among patients with COPD, targeted lung denervation in addition to optimal pharmacotherapy, as compared with pharmacotherapy alone, was associated with fewer respiratory events including exacerbations, according to data from the AIRFLOW-2 study.